SPOTLIGHT -
EP. 1: HCC: Evolving Screening and Surveillance
EP. 2: The Impact of Cirrhosis on Treating HCC
EP. 3: Transplantation Versus Resection in Patients With HCC
EP. 4: Embolization Therapy for Unresectable HCC
EP. 5: Multidisciplinary Systemic Therapy in HCC
EP. 6: Administering Sorafenib in Hepatocellular Carcinoma
EP. 7: Genetic Testing and Second-Line Treatments in HCC
EP. 8: New Approaches in Hepatocellular Carcinoma
EP. 9: Adjuvant and Combination Therapies for HCC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
